AstraZeneca Reports Results of PT027 (albuterol and budesonide) in P-III MANDALA and DENALI Trials for the Treatment of Asthma

September 9, 2021 Auto Bot Asthma, AstraZeneca, Clinical Trials, P-III 0

Shots:

  • The P-III MANDALA & DENALI trial evaluates the efficacy & safety of PT027 (180/160mcg & 180/80mcg doses) vs albuterol & albuterol and budesonide aged ≥4yrs. in 3132 & 1001 patients with asthma
  • Both trials met its 1EPs i.e., reductions in risk of severe exacerbations in the MANDALA trial, improvement in lung function as measured by FEV1 in DENALI trials, safety & tolerability in both trials were consistent with the known profiles of the components
  • PT027 is a fixed-dose combination of albuterol, SABA, budesonide & an inhaled ICS. The therapy is being developed by AstraZeneca and Avillion

Click here to read full press release/ article | Ref: AstraZeneca | Image: PharmaLive

The post AstraZeneca Reports Results of PT027 (albuterol and budesonide) in P-III MANDALA and DENALI Trials for the Treatment of Asthma first appeared on PharmaShots.